Literature DB >> 2114419

Determination of the new fluoroquinolone fleroxacin and its N-demethyl and N-oxide metabolites in plasma and urine by high-performance liquid chromatography with fluorescence detection.

P Heizmann1, D Dell, H Eggers, R Gora.   

Abstract

A high-performance liquid chromatographic method is described for the determination of the new fluoroquinolone fleroxacin and its metabolites in plasma and urine. Plasma samples are deproteinized with acetonitrile, and, after evaporation and reconstitution of the supernatant, samples are analysed on a reversed-phase column. The limit of quantification is 10-20 ng/ml for the parent drug and 10 ng/ml for the metabolites, using a 0.2-ml sample. Urine samples are diluted with the mobile phase. An aliquot is then injected directly onto the column. The limits of quantification are 1 micrograms/ml for the parent drug and 0.5 micrograms/ml for the metabolites, using a 0.1-ml sample. The method has been successfully applied to pharmacokinetic studies of human volunteers and patients.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2114419     DOI: 10.1016/s0378-4347(00)82086-1

Source DB:  PubMed          Journal:  J Chromatogr


  8 in total

1.  Factors influencing elimination and distribution of fleroxacin: metaanalysis of individual data from 10 pharmacokinetic studies.

Authors:  B G Reigner; H A Welker
Journal:  Antimicrob Agents Chemother       Date:  1996-03       Impact factor: 5.191

2.  Disposition of fleroxacin, a new trifluoroquinolone, and its metabolites. Pharmacokinetics in elderly patients.

Authors:  A M Taburet; A Devillers; P Thomare; J P Fillastre; P Veyssier; E Singlas
Journal:  Clin Pharmacokinet       Date:  1990-07       Impact factor: 6.447

3.  Disposition of fleroxacin, a new trifluoroquinolone, and its metabolites. Pharmacokinetics in renal failure and influence of haemodialysis.

Authors:  E Singlas; A Leroy; E Sultan; M Godin; B Moulin; A M Taburet; M Dhib; J P Fillastre
Journal:  Clin Pharmacokinet       Date:  1990-07       Impact factor: 6.447

Review 4.  Fleroxacin clinical pharmacokinetics.

Authors:  A E Stuck; D K Kim; F J Frey
Journal:  Clin Pharmacokinet       Date:  1992-02       Impact factor: 6.447

5.  Single-dose pharmacokinetics of oral fleroxacin in bacteremic patients.

Authors:  J Schrenzel; F Cerruti; M Herrmann; T Leemann; E Weidekamm; R Portmann; B Hirschel; D P Lew
Journal:  Antimicrob Agents Chemother       Date:  1994-06       Impact factor: 5.191

6.  Pharmacokinetics of [18F]fleroxacin in healthy human subjects studied by using positron emission tomography.

Authors:  A J Fischman; E Livni; J Babich; N M Alpert; Y Y Liu; E Thom; R Cleeland; B L Prosser; J A Correia; H W Strauss
Journal:  Antimicrob Agents Chemother       Date:  1993-10       Impact factor: 5.191

Review 7.  Fleroxacin. A review of its pharmacology and therapeutic efficacy in various infections.

Authors:  J A Balfour; P A Todd; D H Peters
Journal:  Drugs       Date:  1995-05       Impact factor: 9.546

8.  Pharmacokinetics of 18F-labeled fleroxacin in rabbits with Escherichia coli infections, studied with positron emission tomography.

Authors:  A J Fischman; E Livni; J Babich; N M Alpert; Y Y Liu; E Thom; R Cleeland; B L Prosser; R J Callahan; J A Correia
Journal:  Antimicrob Agents Chemother       Date:  1992-10       Impact factor: 5.191

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.